GLP-1 medications and health equity: when insurance access determines who benefits
Postgraduate Medical Journal · 22.09.2026
DOI: 10.1093/postmj/qgag128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Postgraduate Medical Journal, online erschienen am 22.09.2026. Verfasst von Samia Arif und 3 weiteren Autor:innen. Beteiligte Einrichtung: King Edward Medical University, Department of Medicine, Neelagumbad, Anarkali, Lahore 54000, Pakistan. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
To the Editor, The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was a therapeutic breakthrough in obesity and type 2 diabetes management. In large randomized controlled trials, semaglutide and tirzepatide reduced weight and cardiovascular risk and provided kidney protection [1–3]. These agents are disease-modifying drugs that affect the pathophysiology of cardiometabolic disease, not simply weight-loss drugs. However‚ access to these therapies is increasingly determined by insurance coverage and socioeconomic status rather than clinical indications. In January 2026, Pennsylvania delisted GLP-1 weight-loss drugs from Medicaid. California followed by similar Medi-Cal restrictions, removing coverage for GLP-1 medications prescribed for weight loss [4]. Obesity is a risk factor for type 2 diabetes‚ heart disease‚ chronic kidney disease‚ and many other chronic diseases with higher prevalence in Black and Hispanic communities [5]. Restrictions on the most effective obesity pharmacotherapy would likely worsen existing health inequalities. There is strong cardiovascular evidence for GLP-1 RAs: in SELECT, semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease, irrespective of diabetes status [1]. In the STEP program‚ tirzepatide in the SURPASS and SURMOUNT trials achieved weight loss exceeding 20% in some people‚ an effect comparable to bariatric surgery [2]. The FLOW trial confirmed the renal protective effect of semaglutide in patients with type 2 diabetes and chronic kidney disease [3]. These data demonstrate that GLP-1 RAs represent multidimensional cardiometabolic therapies‚ conferring benefits across multiple organ systems.
Autor:innen und Institutionen
- King Edward Medical University, Department of Medicine, Neelagumbad, Anarkali, Lahore 54000, Pakistan.
- University of Health Sciences, Department of Medicine, Khayaban-e-Jamia Punjab, Lahore 54600, Pakistan.
- Shaikh Zayed Hospital, Department of Medicine, University Avenue, New Muslim Town, Lahore 54600, Pakistan.
ORCID-Profile: Samia Arif, Amina Chaudhary, Syed Mohib Ullah, Muhammad Shahzaib
Zitieren
APA
Arif, S., Chaudhary, A., Mohib Ullah, S., & Shahzaib, M. (2026). GLP-1 medications and health equity: when insurance access determines who benefits. Postgraduate Medical Journal. https://doi.org/10.1093/postmj/qgag128
Vancouver
Arif S, Chaudhary A, Mohib Ullah S, Shahzaib M. GLP-1 medications and health equity: when insurance access determines who benefits. Postgraduate Medical Journal. 2026. doi:10.1093/postmj/qgag128
BibTeX
@article{Arif2026,
author = {Arif, Samia and Chaudhary, Amina and Mohib Ullah, Syed and Shahzaib, Muhammad},
title = {GLP-1 medications and health equity: when insurance access determines who benefits},
journal = {Postgraduate Medical Journal},
year = {2026},
doi = {10.1093/postmj/qgag128}
}
EUVIMED